Empagliflozin

Empagliflozin (BI 10773, marketed as Jardiance) is a potent, orally bioavailable, selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) protein expressed in the S1 and S2 segments of the renal proximal tubule, where it mediates approximately 90 percent of filtered glucose reabsorption. The compound is a C-aryl glucoside bearing a chlorophenyl core linked to a tetrahydrofuranyloxy-substituted benzyl moiety, and it exhibits the highest selectivity for SGLT2 over the intestinal isoform SGLT1 among the marketed gliflozins, with a selectivity ratio exceeding 2500-fold in heterologous expression systems. By inhibiting SGLT2, empagliflozin produces insulin-independent urinary glucose excretion of approximately 60 to 90 grams in the published literature at therapeutic doses, resulting in reductions in fasting and postprandial plasma glucose, glycated hemoglobin (HbA1c), body weight, and systolic blood pressure without increasing hypoglycemia risk when used as monotherapy. Empagliflozin was developed by Boehringer Ingelheim in collaboration with Eli Lilly and Company, received initial regulatory approval in 2014 for the treatment of type 2 diabetes mellitus, and has since undergone one of the most consequential clinical development programs in modern cardiometabolic medicine. The EMPA-REG OUTCOME trial (2015), enrolling 7020 patients with type 2 diabetes and established cardiovascular disease, demonstrated a 38 percent relative risk reduction in cardiovascular death and a 35 percent reduction in hospitalization for heart failure, results that fundamentally altered the treatment paradigm for type 2 diabetes and prompted regulatory label expansions for cardiovascular risk reduction. The EMPEROR-Reduced trial (2020) demonstrated a 25 percent reduction in the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and reduced ejection fraction regardless of diabetes status, while the EMPEROR-Preserved trial (2021) extended this benefit to patients with heart failure and preserved ejection fraction, a population for which few prior therapies had demonstrated efficacy. The EMPA-KIDNEY trial (2022) demonstrated a 28 percent reduction in the composite of kidney disease progression or cardiovascular death in 6609 patients with chronic kidney disease across a broad range of eGFR values. Pharmacokinetics are characterized by rapid oral absorption with peak plasma concentrations at approximately 1.5 hours, steady-state plasma protein binding of 80 to 86 percent, a terminal elimination half-life of approximately 12.4 hours supporting dosing, and metabolism predominantly through glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 without clinically meaningful cytochrome P450 involvement. The compound has minimal drug-drug interaction potential and does not require dose adjustment for hepatic impairment or mild-to-moderate renal impairment, although efficacy on glycemic endpoints diminishes at lower eGFR values where the filtered glucose load is reduced. The principal adverse events are genital mycotic infections (occurring in approximately 5 to 10 percent of female patients and 1 to 5 percent of male patients), urinary tract infections, volume depletion (particularly in elderly patients and those on concomitant diuretics), and rare but serious events including euglycemic diabetic ketoacidosis and necrotizing fasciitis of the perineum (Fournier gangrene). This monograph reviews the chemistry, synthesis, and structural pharmacology of empagliflozin; the SGLT2 inhibitory mechanism in molecular and physiological detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology across metabolic, cardiovascular, and renal models; the landmark clinical evidence base spanning diabetes, heart failure, and chronic kidney disease; sourcing and quality verification; reconstitution and handling for research applications; stack-interaction considerations; adverse-event signal and safety profile; and a comparative assessment of five alternative SGLT2 inhibitors against empagliflozin on five competency standards.